Jesús F. San Miguel

Jesús F. San Miguel, MD, PhD is Director of the Department of Hematology and Cell Therapy at the Clínica Universidad de Navarra and a professor at CIMA (Center for Applied Medical Research). He is one of Europe's leading authorities on multiple myeloma, internationally recognized for his contributions to establishing MRD (minimal residual disease) assessment as a key endpoint in myeloma clinical trials and for his pivotal role in daratumumab's frontline development. Dr. San Miguel co-led the ALCYONE trial (NEJM 2018), a phase III study demonstrating that adding daratumumab to bortezomib, melphalan, and prednisone (VMP) significantly improved overall survival, progression-free survival, and MRD negativity rates in transplant-ineligible newly diagnosed myeloma patients — establishing daratumumab-VMP as a new standard of care in this population. He has championed the standardization of MRD monitoring in myeloma through ultra-sensitive flow cytometry (next-generation flow, NGF) and next-generation sequencing (NGS) techniques, and has co-authored the EuroFlow and IMWG consensus criteria for MRD assessment. Earlier in his career, Dr. San Miguel contributed to defining the diagnostic criteria for smoldering myeloma and risk stratification models that guide treatment decisions for early intervention. He has published more than 800 peer-reviewed articles, serves on the editorial boards of Blood and JCO, and leads Spain's GEM (Grupo Español de Mieloma) cooperative group.